3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
4
Condylomata Acuminata
4
Papillomavirus Infections
3
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Dysplasia
1
Cancer Survivor
1
Interventions
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
4
human papillomavirus vaccine, L1 type 16, 18
3
Papillomavirus Vaccines
3
Imiquimod
3
Colposcopy
3
Blood Specimen Collection
3
Vaccines
2
VGX-3100
2
Indomethacin
2
Cyclophosphamide
2
Conization
2
fludarabine phosphate
1
fludarabine
1
aldesleukin
1
X-Rays
1
Vaccines, Synthetic
1
Vaccines, DNA
1
Spectrometry, Fluorescence
1
Respiratory Function Tests
1
Proflavine
1
Prochlorperazine
1
Positron-Emission Tomography
1
Polymerase Chain Reaction
1
Pemetrexed
1
Papanicolaou Test
1
Ondansetron
1
Omeprazole
1
O(6)-codeine methyl ether
1
Methods
1
Meperidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Uterine Cervical Dysplasia
×
Vaccines, Synthetic
×
Clear all
NCT03493542
2024-12-31
V501-213
Merck Sharp & Dohme LLC
Phase 3
Completed
766 enrolled
38 charts